AOD-9604 10mg – PharmaTech

AOD-9604 has been studied in preclinical models of lipolysis, lipid metabolism, obesity, adipose-tissue biology, and metabolic regulation, followed by human clinical development programs. The available human evidence, however, did not establish a statistically significant effect on body weight in the pivotal Phase 2b program.

OVERVIEW

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone (hGH). It is structurally related to the hGH C-terminal 177–191 region and incorporates an N-terminal tyrosine modification.

The peptide was developed to investigate the lipolytic and metabolic activity associated with the C-terminal region of growth hormone, while separating these effects from the broader growth-promoting activity of intact GH.

AOD-9604 has been studied in preclinical models of lipolysis, lipid metabolism, obesity, adipose-tissue biology, and metabolic regulation, followed by human clinical development programs. The available human evidence, however, did not establish a statistically significant effect on body weight in the pivotal Phase 2b program.


MECHANISM OF ACTION

C-Terminal hGH Fragment

AOD-9604 is designed around the C-terminal region of human growth hormone rather than the complete 191-amino-acid GH molecule.

Preclinical research investigated whether this region could reproduce aspects of GH-associated fat metabolism, particularly stimulation of lipolysis and modulation of lipid storage, without reproducing the classical GH receptor-mediated growth pathway.

Lipolytic Signaling

Experimental studies have associated AOD-9604 with pathways involving:

  • Adipocyte lipolysis
  • Fatty-acid mobilization
  • Inhibition of lipogenesis
  • Fat oxidation
  • Adipose-tissue metabolic regulation

The precise molecular target responsible for these effects has not been definitively established in humans.

Distinction From Intact Growth Hormone

AOD-9604 should not be considered equivalent to recombinant human growth hormone.

The research hypothesis behind AOD-9604 was that the C-terminal region of GH could influence lipid metabolism independently of the classical GH receptor → IGF-1 growth pathway.


KEY BENEFITS

Research interest in AOD-9604 includes:

  • Lipolysis research
  • Adipocyte biology
  • Fatty-acid metabolism
  • Lipogenesis research
  • Fat oxidation
  • Adipose-tissue signaling
  • Metabolic regulation
  • Obesity research
  • C-terminal GH-fragment biology
  • Comparative GH-fragment research
  • Cartilage and osteoarthritis research

These represent experimental research areas rather than established clinical outcomes.


RESEARCH AREAS

Lipolysis

AOD-9604 has been investigated for its ability to stimulate lipid mobilization in experimental adipocyte and animal models.

Lipogenesis

Preclinical research has examined inhibition of pathways involved in lipid storage and synthesis.

Adipose-Tissue Biology

Research has investigated AOD-9604 in relation to adipocyte metabolism, fatty-acid utilization, and changes in adipose tissue.

Metabolic Research

Experimental models have evaluated the peptide in obesity, insulin sensitivity, energy metabolism, and metabolic dysfunction.

Growth-Hormone Fragment Biology

AOD-9604 provides a research model for investigating biological activity associated with the C-terminal region of GH independently from intact somatotropin.

Cartilage & Joint Biology

AOD-9604 has also been investigated experimentally in models involving cartilage degeneration and osteoarthritis, expanding research beyond its original metabolic development program.


SCIENTIFIC EVIDENCE

The original research program investigated the hypothesis that the lipolytic activity of growth hormone could be separated from its growth-promoting and diabetogenic effects through the use of a C-terminal fragment.

AOD-9604 subsequently entered human obesity-development programs. A 2004 review documented Phase II development underway at that time.

Later FDA review documents describe a Phase 2b study involving approximately 300 participants in which AOD-9604 did not demonstrate a statistically significant difference in body weight versus placebo at the evaluated doses.

Consequently, the current scientific profile should distinguish between:

Preclinical evidence: substantial investigation of lipid metabolism and adipose-tissue biology.

Human evidence: clinical development occurred, but the pivotal weight-loss efficacy endpoint was not successfully demonstrated.

Mechanistic evidence: the precise human molecular target and complete pharmacological mechanism remain incompletely characterized.


MOLECULAR PROFILE

Parameter AOD-9604
Compound class Synthetic C-terminal hGH fragment analogue
Peptide length 16 amino acids
Sequence YLRIVQCRSVEGSCGF
Structural relationship Modified hGH C-terminal fragment
Disulfide bond Cys7–Cys14
Molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular weight ~1,815.1 Da
CAS 221231-10-3
Primary research focus Lipid metabolism / adipose biology
Parent molecule Human growth hormone
Molecular category Synthetic peptide

AOD-9604 is distinct from native hGH Fragment 176–191. The additional N-terminal tyrosine means the two compounds should not be treated as chemically identical.

The intramolecular disulfide bridge between the two cysteine residues is an important structural characteristic of the molecule.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacokinetic Profile

Human pharmacokinetic characterization of AOD-9604 is limited.

FDA review documentation states that human pharmacokinetic or pharmacodynamic studies were not identified for the proposed routes evaluated in its 2024 review. In nonclinical work, AOD-9604 was rapidly degraded in blood, with an approximately 3-minute intravenous half-life reported in pigs.

In vitro studies also demonstrated rapid hydrolysis of the intact peptide in serum, generating smaller peptide fragments.

Accordingly, pharmacokinetic characteristics depend substantially on:

  • Molecular integrity
  • Formulation
  • Route of administration
  • Peptide stability
  • Proteolytic degradation
  • Salt/counterion form
  • Product-specific analytical characteristics

Pharmacodynamic Profile

The proposed experimental pathway can be summarized as:

AOD-9604 → adipose-tissue signaling → lipolytic activity → fatty-acid mobilization

Additional research pathways include:

AOD-9604 → inhibition of lipogenesis → altered lipid-storage dynamics

The precise receptor or molecular target responsible for these effects has not been conclusively established.

Importantly, AOD-9604 should not be assumed to reproduce the complete pharmacodynamic profile of intact human growth hormone.


RESEARCH HIGHLIGHTS

  • Synthetic 16-amino-acid hGH fragment analogue
  • C-terminal GH biology
  • Lipolysis research
  • Adipocyte metabolism
  • Fatty-acid mobilization
  • Lipogenesis research
  • Fat oxidation
  • Adipose-tissue biology
  • Metabolic research
  • Obesity research
  • GH-fragment pharmacology
  • Cartilage research
  • Osteoarthritis models
  • Peptide stability and degradation research

TECHNICAL SPECIFICATIONS

Parameter PharmaTech Specification
Product AOD-9604
Product type Synthetic peptide
Peptide length 16 amino acids
Sequence YLRIVQCRSVEGSCGF
Molecular weight ~1.815 kDa
Disulfide bond Cys7–Cys14
Total quantity [PharmaTech specification]
Chemical form [PharmaTech specification]
Purity ≥ [PharmaTech specification]%
Physical form Lyophilized powder
Appearance White to off-white lyophilized material
Batch [Batch specification]
Storage Controlled refrigerated storage
Research category Metabolic / adipose-tissue biology

STORAGE & HANDLING

Store the lyophilized product under controlled conditions according to the applicable PharmaTech product specification.

Protect from:

  • Excessive heat
  • Direct light
  • Moisture
  • Repeated temperature fluctuations
  • Physical contamination

Maintain the container sealed until laboratory use and handle under appropriate controlled conditions.